As per the announcement, Roivant will integrate the technology within its drug development platform to “improve clinical research and expand access to underserved communities.”
The agreement includes a strategic investment from Roivant, which will enable monARC to expand its patient research networks into additional diseases including atopic dermatitis, obesity, and diabetes, according to the company.
Dan Rothman, Roivant chief information officer and Wasim Malik, PhD, chief digital strategist at Roivant, will join monARC’s board of directors. Additionally, Roivant will collaborate with monARC on five disease areas in which the Roivant family companies are currently conducting clinical research.
The family of companies is testing 23 investigational drugs in 11 therapeutic areas in more than 50 clinical trials.
“Roivant’s drug development team supports the companies in our family as they develop innovative medicines in their respective therapeutic areas,” said William T. Symonds, PharmD, chief development officer, Roivant, in a press release. “monARC’s capabilities will enhance the design and conduct of our own clinical trials, as well as trials conducted by other companies and institutions.”